Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting

2011 ◽  
Vol 25 (2) ◽  
pp. 58-64 ◽  
Author(s):  
Yannick Le Meur ◽  
Richard Borrows ◽  
Mark D. Pescovitz ◽  
Klemens Budde ◽  
Josep Grinyo ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Consensus Meeting ◽  
Therapeutic Drug ◽  
Transplantation Society

Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow–up

1998 ◽  
Vol 30 (8) ◽  
pp. 4068-4069 ◽  
Author(s):  
M Brunet ◽  
J.V Torregrosa ◽  
F Oppenheimer ◽  
J Corbella
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug

scholarly journals Immunosuppressant therapeutic drug monitoring and trough level stabilisation after paediatric liver or kidney transplantation

2019 ◽  
Author(s):  
Klara M. Posfay-Barbe ◽  
Henri Baudet ◽  
Valrie A. McLin ◽  
Paloma Parvex ◽  
Hassib Chehade ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Trough Level ◽  
Therapeutic Drug

Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype

2019 ◽  
Vol 51 (9) ◽  
pp. 2917-2920 ◽  
Author(s):  
L. Allegri ◽  
F. Baldan ◽  
C. Vallone ◽  
P. Tulissi ◽  
M. Gropuzzo ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Cyp3a5 Genotype

The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation

2012 ◽  
Vol 45 (6) ◽  
pp. 1809-1813 ◽  
Author(s):  
Giulia Bedino ◽  
Pasquale Esposito ◽  
Francesca Bosio ◽  
Valeria Corradetti ◽  
Teresa Valsania ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Cytomegalovirus Disease

Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation

2015 ◽  
Vol 37 (5) ◽  
pp. 560-567 ◽  
Author(s):  
Gretchen N. de Graav ◽  
Stein Bergan ◽  
Carla C. Baan ◽  
Willem Weimar ◽  
Teun van Gelder ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

2005 ◽  
Vol 19 (2) ◽  
pp. 145-152 ◽  
Author(s):  
Marc I Lorber ◽  
Claudio Ponticelli ◽  
John Whelchel ◽  
Hartmut W Mayer ◽  
John Kovarik ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Safety Data ◽  
Therapeutic Drug ◽  
Efficacy And Safety

scholarly journals Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring

2021 ◽  
Vol 11 (11) ◽  
pp. 1224
Author(s):  
Eisuke Nakamura ◽  
Tadashi Sofue ◽  
Yasushi Kunisho ◽  
Keisuke Onishi ◽  
Kazunori Yamaguchi ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Drug Monitoring ◽  
Kidney Transplant ◽  
Mycophenolic Acid ◽  
Drug Monitoring ◽  
Target Range ◽  
Therapeutic Drug ◽  
Prognostic Impact ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Mycophenolate mofetil is a key immunosuppressant that is metabolized into mycophenolic acid (MPA). The prognostic impact of MPA-focused therapeutic drug monitoring on allograft prognosis has not been determined in kidney transplant recipients with diabetes. In this study, we assessed the pharmacokinetics of MPA and allograft prognosis in recipients with diabetes. This study retrospectively analyzed 64 adult kidney transplant recipients. MPA blood concentration data (e.g., the time to the maximum concentration (Tmax), and the area under the concentration–time curve from 0 to 12 h (AUC0–12)) were collected at 3 weeks and 3 months after kidney transplantation. Of the 64 recipients, 15 had pre-existing diabetes. At 3 months after kidney transplantation, the Tmax of MPA was significantly longer in recipients with diabetes (mean (standard deviation): 2.8 (2.1) h) than in recipients without diabetes (1.9 (1.1) h, p = 0.02). However, the allograft estimated glomerular filtration rate and acute rejection rate, including borderline change, did not differ according to the diabetes status in patients with adjusted AUC0–12 of MPA within the target range. In conclusion, a longer Tmax of MPA was observed in recipients with diabetes; however, acceptable allograft prognosis was observed in kidney transplant recipients with diabetes and a sufficient AUC0–12 of MPA.

Sign in / Sign up

Export Citation Format

Share Document